Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 13Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Neoplasms 4Lung Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 2Skin Neoplasms 2Skin Diseases 2Pancreatic Neoplasms 2Hematologic Neoplasms 2Uveal Melanoma 1Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Soft Tissue Neoplasms 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Lymphoma 1Lymphatic Metastasis 1Low-grade Serous Ovarian Cancer 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1

Interventions

Imatinib Mesylate 2tipifarnib 1nilotinib 1mirdametinib 1cabozantinib 1binimetinib 1Sunitinib 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Lidocaine 1Glycopyrrolate 1Dexmedetomidine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibromatoses × binimetinib × Clear all
NCT03231306 2025-05-02

NF108-BINI

University of Alabama at Birmingham

Phase 2 Completed
45 enrolled 8 charts
CNS

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡